Cognitive Impairment in Alzheimer's Disease Subtypes

Alzheimer’s disease exhibits considerable heterogeneity in its clinical presentation, especially when comparing early-onset and late-onset forms. While the amnestic phenotype—marked by predominant memory loss—is the most recognised, atypical variants involve deficits in language, visuospatial processing, executive function or behavioural control. Early-onset Alzheimer’s disease (EOAD) often presents before age 65 with more rapid progression, neocortical involvement and non-memory impairments, whereas late-onset Alzheimer’s disease (LOAD) typically manifests after 65 with medial temporal lobe degeneration and predominant amnesia. Genetic factors such as the APOE ε4 allele, together with amyloid-β and tau pathologies, underlie these subtypes but their cognitive signatures differ. Accurate subtyping through neuropsychological assessment and biomarkers informs prognosis, guides personalised interventions and shapes clinical trial design on a global scale.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Cognitive Impairment in Alzheimer's Disease Subtypes publication trend

The graph below shows the total number of articles in cognitive impairment in alzheimer's disease subtypes across all publications each year (not limited to Nature Index journals).

Technical terms

Early-onset Alzheimer’s disease (EOAD): Presentation of Alzheimer’s disease symptoms at or before 65 years of age, often with non-amnestic cognitive deficits.

Late-onset Alzheimer’s disease (LOAD): Presentation of Alzheimer’s disease symptoms after 65 years of age, typically featuring predominant memory loss.

Amyloid-β: Peptide that aggregates into extracellular plaques, one of the core pathological hallmarks of Alzheimer’s disease.

Tau pathology: Intracellular accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles, correlating with neuronal dysfunction.

Positron emission tomography (PET): Functional imaging technique using radiotracers to visualise molecular targets such as amyloid or tau in the living brain.

Neurofilament light chain (NfL): Axonal cytoskeletal protein measurable in blood or cerebrospinal fluid, serving as a marker of neurodegeneration.

References

1. Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease. Alzheimer's Research & Therapy (2024).
2. Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study. Brain Communications (2024).
3. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain (2017).